The Latest News

January 5, 2022

PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech

PRISM BioLab provides the PepMetics® Library, a proprietary library of peptide mimetic small molecules for screening against targets selected by...
Read More
1 2 3 11

About
PRISM BIOLAB

MISSION:
PRISM BioLab is committed to maximizing the potential of its PepMetics® Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.

PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.

PepMetics
Technology

We synthesize like a small molecule, but our PepMetic Molecules act like peptides.

Peptide
MIMETICS

“PepMetics”®
LIBRARY

PRISM’s PepMetics Real Library includes 20,000+ compounds covering various amino acid sequences for screening. The PepMetics Library is used to generate hits for difficult targets.